
Whitney R Steele

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1415738/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Iron deficiency in blood donors: analysis of enrollment data from the REDSâ€II Donor Iron Status Evaluation (RISE) study. Transfusion, 2011, 51, 511-522.	1.6	161
2	Screening Blood Donors for HIV, HCV, and HBV at the American Red Cross: 10-Year Trends in Prevalence, Incidence, and Residual Risk, 2007 to 2016. Transfusion Medicine Reviews, 2020, 34, 81-93.	2.0	36
3	HIV antiretroviral therapy and prevention use in US blood donors: a new blood safety concern. Blood, 2020, 136, 1351-1358.	1.4	32
4	Creutzfeldtâ€Jakob disease lookback study: 21 years of surveillance for transfusion transmission risk. Transfusion, 2017, 57, 1875-1878.	1.6	31
5	HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12â€month deferral policy for men who have sex with men. Transfusion, 2021, 61, 839-850.	1.6	27
6	Prevalence of <scp>human immunodeficiency virus</scp> , <scp>hepatitis B virus,</scp> and <scp>hepatitis C virus</scp> in United States blood donations, 2015 to 2019: The <scp>Transfusionâ€Transmissible</scp> Infections Monitoring System (<scp>TTIMS</scp>). Transfusion, 2020, 60, 2327-2339.	1.6	23
7	HIV residual risk in Canada under a threeâ€month deferral for men who have sex with men. Vox Sanguinis, 2020, 115, 133-139.	1.5	22
8	Research initiatives of blood services worldwide in response to the covidâ€19 pandemic. Vox Sanguinis, 2021, 116, 296-304.	1.5	22
9	Changing the deferral for men who have sex with men – an improved model to estimate HIV residual risk. Vox Sanguinis, 2019, 114, 666-674.	1.5	17
10	Donors deferred for self-reported Chagas disease history: does it reduce risk?. Transfusion, 2014, 54, 2092-2097.	1.6	13
11	Prevalence, incidence, and risk factors of human immunodeficiency virus infection in blood donors in the Southeastern United States. Transfusion, 2017, 57, 404-411.	1.6	12
12	COVIDâ $\in 19$ convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors. Transfusion, 2021, 61, 1471-1478.	1.6	9
13	<scp>HIV</scp> residual risk in Canada for apheresis source plasma donation without deferral for men who have sex with men. Vox Sanguinis, 2022, 117, 201-207.	1.5	7
14	Frequency of rare, serious donor reactions: International perspective. Transfusion, 2021, 61, 1780-1788.	1.6	6
15	Current challenges of severe acute respiratory syndrome coronavirus 2 seroprevalence studies among blood donors: A scoping review. Vox Sanguinis, 2022, 117, 476-487.	1.5	5
16	Use of a rapid electronic survey methodology to estimate blood donors' potential exposure to emerging infectious diseases: Application of a statistically representative sampling methodology to assess risk in US blood centers. Transfusion, 2020, 60, 1987-1997.	1.6	4
17	Young donor health and safety: are we doing enough?. ISBT Science Series, 2015, 10, 20-25.	1.1	2
18	Effectiveness of the postâ€donation instruction sheet in conveying information to repeat blood donors. Vox Sanguinis, 2021, 116, 305-312.	1.5	1